Nicolas Leupin - 27 Feb 2026 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role: Former Chief Medical Officer
Signature: Steven Robbins, as attorney in fact for Leupin, Nicolas
Issuer symbol: NVCR
Transactions as of: 27 Feb 2026
Net transactions value: -$14,060
Form type: 4
Filing time: 03 Mar 2026, 16:09:55 UTC
Previous filing: 06 Mar 2025
Next filing: 05 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Leupin Nicolas	Former Chief Medical Officer	C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE	Steven Robbins, as attorney in fact for Leupin, Nicolas	03 Mar 2026	0002007766

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCR	Ordinary Shares	Sale	$14,060	-1,029	-0.98%	$13.66	104,079	27 Feb 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Nicolas Leupin is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2	This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.

Content

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.